Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Penny Asbell

Ophthalmology Memphis, TN Medical Doctor

NPI 1063473387 CMS profile 93683

930 Madison Ave Ste 200, Memphis, TN 38163

Open in the dashboard

General payments

$130,746

166 records reported · program years 2019–2025

Research payments

$12,355

Paid to them · 14 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$23,381 paid to institutions, not to them · program years 2020–2023

Through program year 2025, Penny Asbell of Memphis, TN is reported in the CMS Open Payments database as having received $130,746 across 166 general payments and $12,355 in research payments paid to them. Separately, studies naming them as principal investigator received $23,381 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,732 18
2025 Research $981 1
2024 General $27,788 56
2024 Research $4,393 6
2023 General $22,133 33
2022 General $6,540 16
2021 General $175 6
2021 Research $2,124 2
2020 General $53,462 13
2020 Research $3,437 3
2019 General $13,916 24
2019 Research $1,420 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Penny Asbell
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Penny Asbell were reported at $6,732. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Penny Asbell Ophthalmology median Middle half National median
2019 $13,916 $258 $104–$655 $163
2020 $53,462 $126 $45–$321 $114
2021 $175 $205 $76–$534 $132
2022 $6,540 $266 $100–$678 $149
2023 $22,133 $308 $117–$745 $160
2024 $27,788 $340 $127–$846 $164
2025 $6,732 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $92,381 70 payments
  2. Horizon Therapeutics plc $9,788 15 payments
  3. AbbVie, Inc. $4,157 6 payments
  4. Dompe Farmaceutici S.p.A. $3,752 2 payments
  5. Harrow Eye, LLC $3,193 7 payments
  6. Amgen Inc. $2,799 5 payments
  7. Kala Pharmaceuticals, Inc. $2,288 3 payments
  8. Bausch & Lomb Americas Inc. $2,095 13 payments
  9. AstraZeneca UK Limited $2,014 3 payments
  10. Recordati_Rare_Diseases_Inc. $1,898 3 payments
  11. Other $6,382 39 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $104,364 65 payments
  2. Travel and Lodging $11,625 17 payments
  3. Honoraria $8,800 4 payments
  4. Food and Beverage $4,780 77 payments
  5. Gift $1,040 1 payment
  6. Education $137 2 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT $92,319 69 payments
  2. TEPEZZA Tepezza $9,758 13 payments
  3. VEVYE $3,005 4 payments
  4. TEPEZZA Inflammation/Rare Disease $2,799 5 payments
  5. FASENRA $2,014 3 payments
  6. BESIVANCE $1,569 2 payments
  7. DEXYCU $1,317 2 payments
  8. MIEBO $339 7 payments
  9. Cequa $312 7 payments
  10. LUMIGAN $269 2 payments
  11. Other $1,891 32 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $12,355 14 payments

Records

180 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record